Antisense Therapeutics Limited (ANP) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 18 PAGES: 33

Antisense Therapeutics Limited (ANP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Antisense Therapeutics Limited (ANP) is a biopharmaceutical company with focus on the

More Info
									          Antisense Therapeutics Limited (ANP) - Financial and Strategic SWOT
                                   Analysis Review
        Reference Code: GDPH58925FSA                                                                                                                          Publication Date: JAN 2014


       Table of Contents
       Table of Contents ............................................................................................................................................................................... 1
          List of Tables .................................................................................................................................................................................. 2
          List of Figures ................................................................................................................................................................................. 3
       Section 1 - About the Company.......................................................................................................................................................... 5
       Antisense Therapeutics Limited - Key Facts ...................................................................................................................................... 5
       Antisense Therapeutics Limited - Key Employees ............................................................................................................................. 6
       Antisense Therapeutics Limited - Key Employee Biographies ........................................................................................................... 7
       Antisense Therapeutics Limited - Major Products and Services......................................................................................................... 8
       Antisense Therapeutics Limited - Pharmaceutical Pipeline Products Data ........................................................................................ 9
          Antisense Therapeutics Limited, Pipeline Products by Therapy Area............................................................................................. 9
          Antisense Therapeutics Limited, Pipeline Products by Development Phase ................................................................................ 10
       Antisense Therapeutics Limited - History ......................................................................................................................................... 12
       Antisense Therapeutics Limited - Company Statement.................................................................................................................... 14
       Antisense Therapeutics Limited - Locations And Subsidiaries ......................................................................................................... 15
          Head Office ................................................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Antisense Therapeutics Limited - Business Description ................................................................................................................... 16
       Antisense Therapeutics Limited - SWOT Analysis ........................................................................................................................... 17
          SWOT Analysis - Overview........................................................................................................................................................... 17
          Antisense Therapeutics Limited - Strengths ................................................................................................................................. 17
             Strength - Diversified Product Pipeline ...................................................................................................................................... 17
             Strength - Isis: Technology Collaboration.................................................................................................................................. 17
          Antisense Therapeutics Limited - Weaknesses ............................................................................................................................ 17
             Weakness - Limited Liquidity Position ....................................................................................................................................... 17
             Weakness - Negative Operating Margin.................................................................................................................................... 17
          Antisense Therapeutics Limited - Opportunities ........................................................................................................................... 17
             Opportunity - Development of ATL1102 .................................................................................................................................... 17
             Opportunity - Emerging Markets ............................................................................................................................................... 18
             Opportunity - Growing Prostate Cancer Market ........................................................................................................................ 18
          Antisense Therapeutics Limited - Threats..................................................................................................................................... 18
             Threat - Competitive Pressures ................................................................................................................................................. 18
             Threat - Tightening of FDA’s Regulatory Oversight ................................................................................................................... 18
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 19
       Antisense Therapeutics Limited - Key Competitors .......................................................................................................................... 20
       Section 3 – Company Financial Ratios ............................................................................................................................................. 21
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 21
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 21
       Performance Chart ........................................................................................................................................................................... 22
       Financial Performance...................................................................................................................................................................... 22
       Financial Ratios - Interim Ratios....................................................................................................................................................... 23



Antisense Therapeutics Limited (ANP) - Financial and Strategic                                                                                                 Reference Code: GDPH58925FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 24
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 25
          Antisense Therapeutics Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 .......................................... 25
          Antisense Therapeutics Limited, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014.......................................... 26
       Antisense Therapeutics Limited, Recent Deals Summary ................................................................................................................ 27
       Section 5 – Company’s Recent Developments ................................................................................................................................ 28
          Antisense Therapeutics Limited, Recent Developments ............................................................................................................... 28
             Oct 28, 2013: ANP to Present at Australia Biotech Invest 2013 ................................................................................................ 28
             Oct 23, 2013: ANP to Present at Canary BioTech and Healthcare Investor Roadshow............................................................ 28
             Aug 28, 2013: ANP to present at and attend major US investment, partnering and industry conferences ................................ 28
             Feb 04, 2013: Antisense Therapeutics To Present Data On Its Product Pipeline At BIO CEO & Investor Conference ............ 28
       Section 6 – Appendix ....................................................................................................................................................................... 29
          Methodology ................................................................................................................................................................................. 29
          Ratio Definitions ............................................................................................................................................................................ 29
          About GlobalData ......................................................................................................................................................................... 33
          Contact Us ......................................................................................................................
								
To top